CClinicalTrials.gg
Status unknownNCT03404102Updated Jan 19, 2018

Discontinuation Rate Among Copper IUD Users

An observational study in Contraceptive Device; Intrauterine, sponsored by noha mohamed elzaydy. Status unknown at 1 site in Egypt. Open to female participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-01-19.

Sponsored by noha mohamed elzaydy · Observational

The sponsor has not verified this record recently (last verified Jan 2018), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Ages
18 Years to 49 Years
Sex
Female
01

Study summary

The intrauterine device (IUD) is one of the most widely used reversible, long-term contraceptive methods in the world. But despite all its advantages; discontinuation rate of IUD ranged from 9.6% to 37.3 % (according to Demographic and Health Surveys data). In Egypt, in 2014, the discontinuation rate of IUD (within 12 months of use) was 14.3%.This study explores the differences around this rate in Egyptian university clinic and primary healthcare clinic with detailed percentages of possible causes.

Read the detailed description

The aim of the study is to compare between primary health care unit and university family planning clinic in discontinuation rate among copper IUD users.

  1. The Research Hypothesis: (Null hypothesis)

    • In women using copper IUD, discontinuation rate in primary health care unit and university clinic may be similar.
  2. The Research Question:

    • In women using copper IUD, Does discontinuation rate in primary health care unit and university clinic differ?
  3. METHODOLOGY:

Patients and Methods

  • Study setting:
  • Family planning Outpatient clinic of Ain Shams Maternity Hospital, (ASUMH)
  • primary health care unit in ain shams area

    • Study population:
  • Study period: 1 year
  • Sample size: was calculated using Sample size computer program 11. After review of literature, no previous similar study was done before, so assume a discontinuation rate of 50% among Cu-IUD users in primary healthcare unit and 25% among Cu-IUD users in university clinic. Based on these values; the study will include 170 Cu-IUD users; equally selected as 85 subjects from each clinic. But due to the expected drop outs, recruitment will start by 200 women from each clinic.

    • Statistics:

      • Descriptive statistics for measured variables will be expressed as range, mean and standard deviation (for metric data); range, median and interquartile range (for discrete data); and number and proportions (for categorical data). Cu-IUD discontinuation findings in each clinic will be compared using the t-test or the Mann-whitney U test depending on whether the measured parameters are guassian variables. A P-value of 0.05 or less will be considered statistically significant.
02

Conditions studied

  • Contraceptive Device; Intrauterine
03

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

women attending family planning for Cu- IUD insertion who meet inclusion criteria

Inclusion criteria

    1. Age from 18-49 years. 2. Women planning for Cu-IUD insertion as a contraceptive method.

Exclusion criteria

Exclusion Criteria:

    1. Any woman with condition included in Category 3 or 4 for Cu-IUD in medical eligibility criteria for contraceptive use (MEC) -World Health Organization-2015.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • university clinic

    * Enrollment: 200 Subjects will be enrolled from women attending family planning clinic for Cu- IUD insertion * Informed Consent: All participants will give their informed consent prior to enrollment. * Data collection \& recording: Data of each patient will be recorded in a Case Record Form (CRF). * Follow up visits /questionnaire: will be conducted from each subject at 6 months and 12 months after Cu-IUD insertion. User satisfaction score and haemoglobin serum level will be included in the questionnaire.

    Device: Cu-IUD

  • primary healthcare unit clinic

    * Enrollment: 200 Subjects will be enrolled from women attending family planning clinic for Cu- IUD insertion * Informed Consent: All participants will give their informed consent prior to enrollment. * Data collection \& recording: Data of each patient will be recorded in a Case Record Form (CRF). * Follow up visits /questionnaire: will be conducted from each subject at 6 months and 12 months after Cu-IUD insertion. User satisfaction score and haemoglobin serum level will be included in the questionnaire.

    Device: Cu-IUD

Interventions

  • DeviceCu-IUD

    Copper Intra-uterine device used as contraceptive method

05

What researchers measure

Primary outcomes

  1. measure discontinuation rate

    • To measure the discontinuation rate among copper IUD users in primary health care unit and university clinic.

    Time frame: 1 year

Secondary outcomes

  1. exclude anemia

    To exclude Anemia from reasons of Cu-IUD discontinuation.

    Time frame: 1 year

  2. comparison

    • To identify reasons of discontinuation among Copper IUD users and percentage of each cause in both university clinic and primary health care unit.

    Time frame: 1 year

  3. users" satisfaction

    • To measure copper IUD users' satisfaction of this contraceptive method in both university clinic and primary health care unit.

    Time frame: 1 year

06

Study locations

1 of 1 sites recruiting
  • Ain Shams Maternity hospital
    Cairo, Ain Shams 11566, Egypt
    Recruiting
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03404102
Lead sponsor
noha mohamed elzaydy
Responsible party
noha mohamed elzaydy (researcher, Ain Shams Maternity Hospital) — Sponsor-investigator
First posted
Jan 19, 2018
Start date
Oct 17, 2017
Primary completion
Jun 2018 (estimated)
Completion
Sep 2018 (estimated)
Last update
Jan 19, 2018

Study contacts

noha elzaydy, M.B.B.Ch.
Contact
nohaelzaydy@gmail.com
01008309518 ext. 202
Ain Shams Maternity Hospital
study director · Ain Shams Maternity Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion